Advanced Men's Health Panel

ApoB (apolipoprotein B) is a protein that coats every atherogenic lipoprotein particle — including LDL, VLDL, IDL, and Lp(a). When we measure LDL, we are estimating the cholesterol content of LDL particles, which can be misleading when particles are small and dense (a pattern common in metabolic syndrome). ApoB, by contrast, counts the actual number of atherogenic particles regardless of their cholesterol content. Multiple large-scale studies have shown that ApoB is more predictive of cardiovascular events than LDL, particularly in men with normal LDL but high particle number. The 2023 ESC guidelines now recommend ApoB as the preferred measure of atherogenic risk.

Lipoprotein(a) — Lp(a) — is a modified form of LDL with an additional protein (apolipoprotein(a)) attached. It is strongly determined by genetics, meaning lifestyle and diet changes make very little difference to its level. Approximately 20 to 25% of the population carry elevated Lp(a), which significantly increases the risk of heart attack, stroke, and aortic valve disease — independently of standard cholesterol levels. Currently there are no licenced medications that specifically lower Lp(a) in the UK (RNA therapies are in late-stage trials), but knowing your Lp(a) level guides the aggressiveness of other cardiovascular risk reduction: statin therapy to bring LDL as low as possible, blood pressure control, and lifestyle optimisation become even more important.

Homocysteine is an amino acid produced during methionine metabolism. Elevated homocysteine (hyperhomocysteinaemia) is associated with endothelial damage, increased thrombotic risk, and independent cardiovascular disease risk. High homocysteine often reflects deficiency in the B-vitamins required to metabolise it — particularly B12, folate, and B6. Unlike Lp(a), elevated homocysteine is usually treatable: supplementation with B12, folate, and B6 can reliably lower homocysteine levels, and there is evidence that this reduces cardiovascular event risk, particularly in those with documented deficiency.

Men produce oestradiol through the conversion of testosterone by aromatase enzymes, found primarily in fat tissue, liver, and bone. Oestradiol in men is essential for: maintaining bone density (low oestradiol in men causes osteoporosis as readily as in women); regulating libido and erectile function; protecting the cardiovascular system; and supporting healthy cognitive function. In men on TRT without monitoring, oestradiol can become elevated (causing gynaecomastia, water retention, and mood changes) or, if an aromatase inhibitor is used aggressively, become too low (causing joint pain, poor bone density, and low libido despite adequate testosterone).

Ferritin reflects iron stores, but can be misleadingly elevated in inflammation (as an acute-phase protein) even when true iron stores are low. Including serum iron, transferrin saturation, and TIBC (total iron-binding capacity) gives a more complete and reliable iron status picture. Low serum iron with low transferrin saturation and high TIBC indicates true iron deficiency. Low serum iron with normal or elevated ferritin suggests iron sequestration due to chronic inflammation. For men — who are less commonly deficient than women but can develop iron overload (haemochromatosis) or iron deficiency from gastrointestinal causes — this fuller iron status picture is clinically important.

Ideally at 35 or earlier if there is a strong family history of premature cardiovascular disease (heart attack before 60 in a first-degree relative, or familial hypercholesterolaemia). Lp(a) only needs to be measured once in most individuals since it is genetically determined and does not change significantly over time. ApoB is useful to monitor in parallel with LDL, particularly if LDL appears controlled but cardiovascular risk remains unexplained. For men with no significant risk factors, a first ApoB and Lp(a) measurement by 40 is a reasonable baseline to establish cardiovascular risk before any primary prevention decisions are made.